Navigation Links
New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyl's HNO Donors As Novel Treatments For Heart Failure
Date:10/28/2013

art failure models. The investigators concluded that the combination of effects differentiates HNO donors from other classes of inotropes or ino-dilators, and provides a strong rationale for continuing studies to develop donors with optimized pharmacology for the treatment of congestive heart failure.

"Cardioxyl is excited about these results obtained with our first-generation HNO donor, and is poised to expand upon this data as we prepare to bring our second-generation HNO donor into the clinic next year," said Chris Kroeger, M.D., Cardioxyl's President and Chief Executive Officer.

The study is available online, via subscription, at http://circheartfailure.ahajournals.org/content/early/2013/10/09/CIRCHEARTFAILURE.113.000632

About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is focused on the discovery and development of new classes of safe and effective therapeutic agents for the treatment of cardiovascular disease. Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl (HNO) technology. The company's core HNO platform has generated several pre-clinical and clinical candidates. Cardioxyl is a privately held company financed by life science venture investors, including New Enterprise Associates, OrbiMed, Aurora Funds and Osage University Partners.


'/>"/>
SOURCE Cardioxyl Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ARUP Laboratories Presents Recent Findings at PAINWeek
2. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
3. Key Findings: Innovations in Ophthalmic Devices - Anterior Segment
4. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
5. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
6. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
7. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
8. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
9. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
10. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
11. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  Hologic, Inc. (NASDAQ: HOLX ... fiscal third quarter ended June 27, 2015.  Quarterly revenues ... and 12.2% on a constant currency basis.  GAAP earnings ... EPS of $0.43 increased 16.2%. "Our third ... made in building a company that can grow sustainably ...
(Date:7/29/2015)... Inc. (NASDAQ: NBIX ) today announced its financial results for ... 2015, the Company reported a net loss of $24.0 million, or ... million, or $0.18 loss per share, for the same period in ... reported a net loss of $25.2 million, or $0.30 loss per ... loss per share, for the first half of last year. ...
(Date:7/29/2015)... July 29, 2015  Depomed, Inc. (Nasdaq: DEPO ... for the quarter ended June 30, 2015. ... pain and neurology marketplace, with significant net product revenue ... value to our shareholders in both the immediate and ... Depomed. "Growth in the second quarter was led by ...
Breaking Medicine Technology:Hologic Announces Financial Results for Third Quarter of Fiscal 2015 2Hologic Announces Financial Results for Third Quarter of Fiscal 2015 3Hologic Announces Financial Results for Third Quarter of Fiscal 2015 4Hologic Announces Financial Results for Third Quarter of Fiscal 2015 5Hologic Announces Financial Results for Third Quarter of Fiscal 2015 6Hologic Announces Financial Results for Third Quarter of Fiscal 2015 7Hologic Announces Financial Results for Third Quarter of Fiscal 2015 8Hologic Announces Financial Results for Third Quarter of Fiscal 2015 9Hologic Announces Financial Results for Third Quarter of Fiscal 2015 10Hologic Announces Financial Results for Third Quarter of Fiscal 2015 11Hologic Announces Financial Results for Third Quarter of Fiscal 2015 12Hologic Announces Financial Results for Third Quarter of Fiscal 2015 13Hologic Announces Financial Results for Third Quarter of Fiscal 2015 14Hologic Announces Financial Results for Third Quarter of Fiscal 2015 15Hologic Announces Financial Results for Third Quarter of Fiscal 2015 16Hologic Announces Financial Results for Third Quarter of Fiscal 2015 17Hologic Announces Financial Results for Third Quarter of Fiscal 2015 18Hologic Announces Financial Results for Third Quarter of Fiscal 2015 19Hologic Announces Financial Results for Third Quarter of Fiscal 2015 20Hologic Announces Financial Results for Third Quarter of Fiscal 2015 21Hologic Announces Financial Results for Third Quarter of Fiscal 2015 22Hologic Announces Financial Results for Third Quarter of Fiscal 2015 23Hologic Announces Financial Results for Third Quarter of Fiscal 2015 24Hologic Announces Financial Results for Third Quarter of Fiscal 2015 25Neurocrine Biosciences Reports Second Quarter 2015 Results 2Neurocrine Biosciences Reports Second Quarter 2015 Results 3Neurocrine Biosciences Reports Second Quarter 2015 Results 4Neurocrine Biosciences Reports Second Quarter 2015 Results 5Neurocrine Biosciences Reports Second Quarter 2015 Results 6Neurocrine Biosciences Reports Second Quarter 2015 Results 7Neurocrine Biosciences Reports Second Quarter 2015 Results 8Neurocrine Biosciences Reports Second Quarter 2015 Results 9Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 2Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 3Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 Guidance 4
... SAN DIEGO and JERUSALEM, May 17, 2012  Ambit Biosciences ... ) ("Teva") today announced the clearance of an Investigational New ... Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor.  ... promising therapeutic potential for this agent, as evidenced by ...
... May 17, 2012 - Atu027, a First ... Activity in Cancer Patients and Possible Biomarker Identified ... of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting ... "Company"), a leading global RNA interference (RNAi) therapeutics company, today ...
Cached Medicine Technology:Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 2Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 3Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 4Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor 5New Data from Silence's Atu027 Anticancer Trial Published at ASCO 2New Data from Silence's Atu027 Anticancer Trial Published at ASCO 3New Data from Silence's Atu027 Anticancer Trial Published at ASCO 4New Data from Silence's Atu027 Anticancer Trial Published at ASCO 5
(Date:7/29/2015)... , ... July 29, 2015 , ... Join Luz Delia ... healthfulness. Gerber believes that Well-Being begins with understanding how the body actually works. A ... of healthfulness within. Guests will receive tips on how to forge this new relationship ...
(Date:7/29/2015)... Foxborough, MA (PRWEB) , ... July 29, 2015 , ... ... at Gillette Stadium featuring Brazil vs. USA . , The international ... 2015, it has grown exponentially and now on September 8th, one of the world’s ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA ... five-year period, expiring November 30, 2019, during its recent meeting. , The Commission ... demonstrating the program’s compliance with the NCCA’s Standards for the Accreditation of Certification ...
(Date:7/29/2015)... ... 2015 , ... On July 26th the Miami Herald ... nicotine laced liquid products. Their report says cigarette use has decreased recently to ... troublesome to addiction professionals as many of the candy flavors available are too ...
(Date:7/29/2015)... ... July 29, 2015 , ... With a new community ... with Stillwaters Cancer Support Services and announced a new charity campaign to raise ... counseling, support groups, workshops and educational programs at no charge. Scott Campbell ...
Breaking Medicine News(10 mins):Health News:Pampering and Empowerment Abound at Final Event in Luz Delia Gerber’s Book Unveiling 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3
... windows to the soul, as the old adage goes, but scientists ... may become the basis for a long-sought test to detect infection ... help prevent the disease from spreading in the food supply. A ... with the Mad Cow agent appears in ACS, semi-monthly journal ...
... fatigue is often a major problem for cancer ... completing therapy. Researchers at Mayo Clinic ( http://www.mayoclinic.org/oncology-rst/ ... ( http://ncctg.mayo.edu/ ) (NCCTG) recently completed a study ... and found that, while it did not improve ...
... Wedding ... this important event in your life. , ... Richmond, VA (PRWEB) June 2, 2010 -- Wedding bells and sleepless nights can go hand-in-hand this ... getting married not only is one of the most important events in a person’s life, it’s ...
... Quebec June 1, 2010 Middle-aged Canadians are much ... of whom are close to panic, says an Alberta researcher ... she says the differing attitudes today may foreshadow growing differences ... age. Susan McDaniel, a sociology researcher and demographics expert, ...
... after mastectomy fared better, researchers say , WEDNESDAY, June ... after a mastectomy may influence the odds of breast ... the Catholic University of Louvain (Leuven) in Belgium looked ... in 327 women from one to four years after ...
... ... laser treatments for stretch marks and scars which could help up to 23 million women ... (PRWEB) May 30, 2010 -- The Harley ... for stretch marks on the market, which promises to reduce the appearance of stretch marks, medically ...
Cached Medicine News:Health News:Results from a study testing methylphenidate for cancer-related fatigue 2Health News:Results from a study testing methylphenidate for cancer-related fatigue 3Health News:A Good Night's Sleep Can Help Reduce June Wedding Planning Stress 2Health News:Survey highlights major Canada-US differences in people in middle age 2Health News:The Harley Medical group launches exclusive treatment for stretch marks and scars 2Health News:The Harley Medical group launches exclusive treatment for stretch marks and scars 3
...
... designed for patient comfort as well as dependable ... at 5cm intervals and line marked each centimeter., ... available spanning most clinical needs and the range ... or two sensors., ,A range of four ...
... The Standard VersaFlex™ disposable pH ... nurses, and clinics worldwide for evaluating ... catheters for 24-hour esophageal pH monitoring. ... the smallest diameter esophageal catheter on ...
FLEXILOG accessory....
Medicine Products: